But using a dermaroller or a dermastamp isn't a dermabrasion.
Lots Of New Info On Follica's Website
- Thread starter stump
- Start date
But using a dermaroller or a dermastamp isn't a dermabrasion.
Couple thoughts....
1. If follica was wanting more investors, shouldnt they put a few results photo on their website too. That would surely get plenty of ppl interested, if it worked, right?
2. We are now assuming follica is using a new compound ( not minoxidil). If this were true wouldn't it have to be in testing right now to be released by 2018. So far I haven't I heard of anyone finding any evidence of a new compound being tested.
Is there any way we can search for trials the folica might be conducting on novel compounds?
3. I hate the first picture on the main page of the hairlosstalk website. It's the pic of the bald guy laying there and he has a girl resting on him. But she looks so uninterested and disappointed and I imagine she's thinking about a guy with lots and lots of hair. This image makes me sad
1. If follica was wanting more investors, shouldnt they put a few results photo on their website too. That would surely get plenty of ppl interested, if it worked, right?
2. We are now assuming follica is using a new compound ( not minoxidil). If this were true wouldn't it have to be in testing right now to be released by 2018. So far I haven't I heard of anyone finding any evidence of a new compound being tested.
Is there any way we can search for trials the folica might be conducting on novel compounds?
3. I hate the first picture on the main page of the hairlosstalk website. It's the pic of the bald guy laying there and he has a girl resting on him. But she looks so uninterested and disappointed and I imagine she's thinking about a guy with lots and lots of hair. This image makes me sad
Noisette
Established Member
- Reaction score
- 1,341
Hi
Of course this on a puretech health's pdf : http://puretechhealth.com/images/investors/Puretech_Pi_e-Prospectus_Final_T08_CNB-v2.pdf
Here we can see that new hair follicles were observed in 3 humans studies.
I don't know for sure if Follica wants more investors because Puretech Health is their co-founder and main Investor. They want some partners.
" 7.8 Business plan and commercialisation strategy
Follica is currently developing product specifications for a system consisting of a proprietary medical procedure using medical devices and consumable components. These device concepts are based on the results of the company’s completed human pilot studies and other external supportive research. The company aims to complete product development including the design of high-value disposable devices in 2016 and subsequently initiate a pivotal clinical trial.
Thereafter, Follica plans to seek FDA 510(k) clearance using data from a pivotal clinical trial at multiple clinical sites within and potentially also outside the US. The pivotal trial for the in-office procedure is expected to be initiated during 2016 and would be expected to complete in 2017. If the clinical data is favourable, Follica would plan to seek FDA clearance in 2017, with commercial release to potentially follow in 2018 in the US. The company may consider establishing a relationship with an external corporate partner to assist with the launch and marketing of its products, in the form of a co-promotion or similar agreement. The proceeds allocated to Follica as a result of the Offer are expected to be sufficient to fund Follica through FDA clearance. Follica’s business model focuses on the provision of its patented procedure, devices and consumables to clinicians and their patients seeking treatment for hair loss, as well as the company’s at-home medical devices to healthcare, cosmetics and similar retail organisations, offering hair loss treatments and related devices to their customers. The company intends to develop one or more partnerships to assist in the launch and promotion of its product candidates in both US and other markets, in the form of a co-promotion or similar arrangement. As such, the company’s commercialisation plan involves two distribution channels"
Last edited:
Thanks Noisette! Some of the largest privately held companies are: Toys R Us, Cargill, Koch Industries, Bechtel, Meijer Groceries, Enterprise Rent-a-Car etc. And, private companies don't have to report quarterly earnings and other data to the SEC. More control for the owners.
Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas.
https://www.ncbi.nlm.nih.gov/pubmed/19358281
Abstract
We had previously reported that aryl hydrocarbon receptors (AhRs) are overexpressed in lung adenocarcinomas. Benzo[a]pyrene (BaP), an AhR agonist, increased FGF-9 expression in human lung adenocarcinoma cells. Similarly, several AhR agonists increased FGF-9 mRNA levels, and BaP-induced FGF-9 expression was prevented by cotreatment with AhR antagonist in human lung adenocarcinoma cells. Furthermore, AhR agonists increased transcriptional activity of FGF-9 promoter. Modulation of AhR expression via RNA interference or transient overexpression respectively reduced or increased both constitutive and BaP-induced FGF-9 expression in human lung cells. These results suggested that AhR activation and overexpression increased FGF-9 expression in lung cells. FGF-9 increased growth of lung fibroblasts but not that of lung adenocarcinoma cells. However, conditioned media collected from FGF-9-treated fibroblasts increased cell growth of lung adenocarcinoma cells. Furthermore, lung adenocarcinoma cells expressed FGF receptor 2 and cotreatment with anti-FGF receptor 2 prevented the interaction between fibroblasts and tumor cells. It is likely that FGF-9-stimulated fibroblasts secreted unknown factors, which activated FGF receptor 2 and subsequently promoted growth of lung adenocarcinoma cells. We further compared AhR and FGF-9 expression in 146 non-small cell lung cancer (NSCLC) cases by immunohistochemistry. FGF-9 expression was more common in adenocarcinomas than in squamous cell carcinomas. Furthermore, FGF-9 and AhR expression were well correlated in lung adenocarcinomas. These results suggest that AhR expression correlated positively with FGF-9 expression in lung adenocarcinomas, which might promote tumor growth by modulating communication between tumor cells and fibroblasts. Preventing AhR overexpression or disturbing FGF-9 function may reduce the development of lung adenocarcinomas. (c) 2009 UICC.
https://www.ncbi.nlm.nih.gov/pubmed/19358281
Abstract
We had previously reported that aryl hydrocarbon receptors (AhRs) are overexpressed in lung adenocarcinomas. Benzo[a]pyrene (BaP), an AhR agonist, increased FGF-9 expression in human lung adenocarcinoma cells. Similarly, several AhR agonists increased FGF-9 mRNA levels, and BaP-induced FGF-9 expression was prevented by cotreatment with AhR antagonist in human lung adenocarcinoma cells. Furthermore, AhR agonists increased transcriptional activity of FGF-9 promoter. Modulation of AhR expression via RNA interference or transient overexpression respectively reduced or increased both constitutive and BaP-induced FGF-9 expression in human lung cells. These results suggested that AhR activation and overexpression increased FGF-9 expression in lung cells. FGF-9 increased growth of lung fibroblasts but not that of lung adenocarcinoma cells. However, conditioned media collected from FGF-9-treated fibroblasts increased cell growth of lung adenocarcinoma cells. Furthermore, lung adenocarcinoma cells expressed FGF receptor 2 and cotreatment with anti-FGF receptor 2 prevented the interaction between fibroblasts and tumor cells. It is likely that FGF-9-stimulated fibroblasts secreted unknown factors, which activated FGF receptor 2 and subsequently promoted growth of lung adenocarcinoma cells. We further compared AhR and FGF-9 expression in 146 non-small cell lung cancer (NSCLC) cases by immunohistochemistry. FGF-9 expression was more common in adenocarcinomas than in squamous cell carcinomas. Furthermore, FGF-9 and AhR expression were well correlated in lung adenocarcinomas. These results suggest that AhR expression correlated positively with FGF-9 expression in lung adenocarcinomas, which might promote tumor growth by modulating communication between tumor cells and fibroblasts. Preventing AhR overexpression or disturbing FGF-9 function may reduce the development of lung adenocarcinomas. (c) 2009 UICC.
- Reaction score
- 479
HAHAHAH!!! GOLDEN!!!
You just made my day.
- Reaction score
- 2,634
Wont matter, if its booked for you it'll be booked for non-booked americans too.
Dermabrasion is just sanding your skin, beauty parlors have been doing it for years.
Follica has created untold numbers of cosmetically useless follicles in the last decade. Without some assurance that you are copying exactly the right protocol it will probably be a waste of time. They have a long habit of hiding their current research and only going public with outdated stuff. This a not a publicly-traded company. They have no incentive to impress the public for fund-raising.
And I do mean your TIME would be wasted. Every dermabrasion session takes most of a year to heal up enough for another round of it. Even then, I wouldn't want to be repeating the procedure on the same spot any more than necessary. It's not a big bloody scalping session but it is HARD on your skin.
And I do mean your TIME would be wasted. Every dermabrasion session takes most of a year to heal up enough for another round of it. Even then, I wouldn't want to be repeating the procedure on the same spot any more than necessary. It's not a big bloody scalping session but it is HARD on your skin.
- Reaction score
- 2,634
We could use these
Ouch.
Although what I've once done with my dermaroller, is press it in as deep as I could and TWIST it around, shredding my skin. Holy christ was it painful.
KO1
Established Member
- Reaction score
- 101
Hmm...the problem is, I don't think Follica has actually done 3 clinical studies in humans. There is record of only one clinical trial, and that was conducted in Germany from 2010-2011. The other one was a pilot test done at Harvard in 2008, where all they did was dermabrasion.
I believe the "third" study Follica is talking about is the Indian Dermarolling study done by Dhurat et al. So not Follica....
I believe the "third" study Follica is talking about is the Indian Dermarolling study done by Dhurat et al. So not Follica....
KO1
Established Member
- Reaction score
- 101
It's interesting that they use the word "drugs" in the plural. I wonder what else they could be using, apart from minoxidil. What's also curious is this:
Over time and with the administration of a variety of compounds including approved drugs, these fully differentiated new follicles would undergo the normal steps of the hair growth cycle, resulting in the growth of new hair.
"Over time"....maybe they are expecting the primitive hair follicle structures to mature into full terminal hairs?
Follica intends for this device to also be made available to patients experiencing hair loss who are not undergoing the company’s in-office procedure.
So like....a topical basically.
My opinion on this company is that their science is good and promising, but I don't think it's quite mature enough for prime time. Hopefully I am wrong.
Over time and with the administration of a variety of compounds including approved drugs, these fully differentiated new follicles would undergo the normal steps of the hair growth cycle, resulting in the growth of new hair.
"Over time"....maybe they are expecting the primitive hair follicle structures to mature into full terminal hairs?
Follica intends for this device to also be made available to patients experiencing hair loss who are not undergoing the company’s in-office procedure.
So like....a topical basically.
My opinion on this company is that their science is good and promising, but I don't think it's quite mature enough for prime time. Hopefully I am wrong.
- Reaction score
- 2,634
All the treatments work 'with time' anyway. Hair transplants take up to and over a year for full effects.
How long will it take Follica's treatment to work if they haven't finished inventing it yet?
AFAIK there have only been those few human trials already mentioned. Those were not encouraging.
What else could they be banking on? Mouse results? B*tch, please.
.
AFAIK there have only been those few human trials already mentioned. Those were not encouraging.
What else could they be banking on? Mouse results? B*tch, please.
.